Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Enters $500M Credit Facility

NEW YORK – PerkinElmer has entered into a $500 million credit facility to pay, in part, its $5.25 billion acquisition of BioLegend, the Waltham, Massachusetts-based company said in a document filed with the US Securities and Exchange Commission on Thursday.

PerkinElmer entered into the unsecured delayed draw term loan credit facility on Aug. 11 with Bank of America as administrative agent. Other lenders include Goldman Sachs, JP Morgan Chase, and Wells Fargo, PerkinElmer said in the SEC document. The credit facility provides for a $500 million committed term loan to fund, in part, PerkinElmer's buy of BioLegend, to refinance certain indebtedness of BioLegend, and to pay fees and expenses associated with the acquisition and its financing.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.